Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings
Haemonetics' (HAE) first-quarter fiscal 2025 results are likely to reflect the benefits of hemostasis management growth.
HAE vs. BSX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
HAE or BSX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
Here's Why Haemonetics (HAE) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics (HAE) Banks on Growing Hospital Arm, New Launches
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.
Top Medical Stocks to Buy for Growth & Performance
The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.
Wall Street Analysts Think Haemonetics (HAE) Could Surge 33.2%: Read This Before Placing a Bet
The consensus price target hints at a 33.2% upside potential for Haemonetics (HAE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Haemonetics (HAE) Loses -5.16% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Haemonetics (HAE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Haemonetics faces near-term revenue growth challenges due to the loss of its plasma collections business with CSL over the next two years. Management has used M&A to boost its revenue growth, including the very successful deal for Cardiva to enter vascular closure, but recent M&A deals have been more questionable. Haemonetics should see revenue reacceleration in FY'26, with long-term revenue growth of 6% to 7% and margin improvement driving a fair value above $100.
Haemonetics (HAE) Expands VASCADE Line With New Limited Launch
Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.
HAE vs. BSX: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
